| Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. (NCT07181785) | Andrés José Maria Ferreri | 2022-07-12 |
| Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients (NCT06760936) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-06-06 |
| Bio-CAR-T BS Study (NCT05366569) | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2022-04-26 |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (NCT05131022) | Nurix Therapeutics, Inc. | 2022-04-13 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas (NCT04933617) | National Cancer Institute (NCI) | 2022-03-24 |
| IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study (NCT07493486) | Zhejiang Cancer Hospital | 2022-02-01 |
| Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) (NCT04456023) | Novartis Pharmaceuticals | 2022-01-31 |
| A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (NCT05169489) | Regeneron Pharmaceuticals | 2022-01-24 |
| A Study of NX-1607 in Adults With Advanced Malignancies (NCT05107674) | Nurix Therapeutics, Inc. | 2021-09-29 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies (NCT04830137) | Nurix Therapeutics, Inc. | 2021-05-05 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies (NCT04824794) | Genmab | 2021-03-09 |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (NCT04836507) | Curocell Inc. | 2021-03-02 |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (NCT04767308) | Huazhong University of Science and Technology | 2021-03-01 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) (NCT05349201) | Novartis Pharmaceuticals | 2020-12-09 |
| Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL) (NCT05366257) | Novartis Pharmaceuticals | 2020-08-17 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant (NCT05526313) | Chengdu Zenitar Biomedical Technology Co., Ltd | 2020-08-10 |
| A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04231747) | Juno Therapeutics, a Subsidiary of Celgene | 2020-05-21 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels (NCT04537715) | Epizyme, Inc. | 2020-04-23 |
| Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT03936153) | Xynomic Pharmaceuticals, Inc. | 2020-01-20 |
| A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin (NCT04624893) | Jiangsu Cancer Institute & Hospital | 2019-12-12 |
| ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (NCT04049513) | Malaghan Institute of Medical Research | 2019-10-11 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (NCT03571828) | Amgen | 2018-10-29 |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML (NCT03547115) | MEI Pharma, Inc. | 2018-05-31 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma (NCT02914938) | MEI Pharma, Inc. | 2016-10-01 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study (NCT02875548) | Epizyme, Inc. | 2016-08-30 |
| Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT02570542) | Memorial Sloan Kettering Cancer Center | 2015-10-01 |
| Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (NCT02445248) | Novartis Pharmaceuticals | 2015-07-29 |
| A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT02957019) | Philogen S.p.A. | 2013-07-31 |
| Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy (NCT01829958) | Memorial Sloan Kettering Cancer Center | 2013-04-01 |
| Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP (NCT02983097) | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | 2010-11-01 |
| DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma (NCT01066429) | Hospital Universitario Principe de Asturias | 2009-12-01 |
| Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) (NCT01054781) | Samsung Medical Center | 2009-01-01 |
| A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 (NCT00400478) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2006-01-01 |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL (NCT01148446) | Fondazione Italiana Linfomi - ETS | 2003-01-01 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NCT00001337) | National Cancer Institute (NCI) | 1993-05-08 |
| A Compassionate Use (CU) Program of Odronextamab (NCT05619367) | Regeneron Pharmaceuticals | |
| Karyopharm Expanded Access Program for Selinexor (NCT07215832) | Karyopharm Therapeutics Inc | |